<DOC>
	<DOCNO>NCT01650246</DOCNO>
	<brief_summary>This study ass serum uric acid lower effect safety lesinurad long-term timeframe .</brief_summary>
	<brief_title>Open-Label Lesinurad Monotherapy Extension Study Gout</brief_title>
	<detailed_description>This Phase 3 , open-label , uncontrolled , extension study ass long-term efficacy safety lesinurad monotherapy subject complete double-blind treatment period Study RDEA594-303 .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject able understand study procedures risk involve willing provide write informed consent first study related activity . Subject complete doubleblind treatment period Study RDEA594303 actively receive tolerate study medication ( lesinurad placebo ) Month 6 visit . Subject willing adhere visit/protocol schedule . Subject male female ; female subject childbearing potential must agree use effective nonhormonal method birth control study least 14 day last dose study medication . Subject medical psychological condition , opinion Investigator and/or Medical Monitor , might create undue risk subject interfere subject 's ability comply protocol requirement complete study . Subject past medical history urolithiasis , nephrolithiasis , kidney stone diathesis . Subject develop kidney stone Study RDEA594303</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>